CA2886747C - Treating vascular disease and complications thereof - Google Patents

Treating vascular disease and complications thereof Download PDF

Info

Publication number
CA2886747C
CA2886747C CA2886747A CA2886747A CA2886747C CA 2886747 C CA2886747 C CA 2886747C CA 2886747 A CA2886747 A CA 2886747A CA 2886747 A CA2886747 A CA 2886747A CA 2886747 C CA2886747 C CA 2886747C
Authority
CA
Canada
Prior art keywords
antibody
human subject
pharmaceutical composition
administration
use according
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CA2886747A
Other languages
English (en)
French (fr)
Other versions
CA2886747A1 (en
Inventor
John Simard
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Xbiotech Inc
Original Assignee
Janssen Biotech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc filed Critical Janssen Biotech Inc
Publication of CA2886747A1 publication Critical patent/CA2886747A1/en
Application granted granted Critical
Publication of CA2886747C publication Critical patent/CA2886747C/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244Interleukins [IL]
    • C07K16/245IL-1
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Surgery (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
CA2886747A 2012-10-04 2013-10-01 Treating vascular disease and complications thereof Active CA2886747C (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201261709754P 2012-10-04 2012-10-04
US61/709,754 2012-10-04
PCT/US2013/062903 WO2014055544A1 (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Publications (2)

Publication Number Publication Date
CA2886747A1 CA2886747A1 (en) 2014-04-10
CA2886747C true CA2886747C (en) 2023-12-05

Family

ID=50432830

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2886747A Active CA2886747C (en) 2012-10-04 2013-10-01 Treating vascular disease and complications thereof

Country Status (12)

Country Link
US (3) US20140099321A1 (enExample)
EP (3) EP4628162A3 (enExample)
JP (1) JP6460993B2 (enExample)
KR (2) KR102296017B1 (enExample)
CN (2) CN104684929A (enExample)
AU (1) AU2013327501B2 (enExample)
CA (1) CA2886747C (enExample)
HK (1) HK1211960A1 (enExample)
IL (1) IL237765B (enExample)
MX (1) MX376241B (enExample)
RU (1) RU2671955C2 (enExample)
WO (1) WO2014055544A1 (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6324720B2 (ja) 2010-06-18 2018-05-16 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 関節炎治療
KR102748255B1 (ko) 2010-08-23 2024-12-31 엑스바이오테크 인코포레이티드 종양성 질병들에 대한 치료
US9724409B2 (en) 2011-04-01 2017-08-08 Xbiotech, Inc. Treatment of inflammatory skin disease
JP6204915B2 (ja) 2011-09-23 2017-09-27 エックスバイオテク, インコーポレイテッドXbiotech, Inc. 悪液質治療
US9545441B2 (en) 2012-09-18 2017-01-17 Xbiotech, Inc. Treatment of diabetes
KR20190117579A (ko) 2017-02-16 2019-10-16 엑스바이오테크, 인크. 화농성 한선염의 치료
CN113874034A (zh) * 2019-05-03 2021-12-31 苏黎世大学 脑缺血再灌注损伤的治疗
KR102652849B1 (ko) 2022-03-14 2024-04-01 한국화학연구원 극성 아라미드 나노섬유로 제조한 하이드로겔

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH652145A5 (de) 1982-01-22 1985-10-31 Sandoz Ag Verfahren zur in vitro-herstellung von hybridomen welche humane monoklonale antikoerper erzeugen.
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
RU2235541C2 (ru) * 1994-10-04 2004-09-10 Эмори Юниверсити Лечение атеросклероза и других сердечно-сосудистых и воспалительных заболеваний
JP2003500069A (ja) * 1999-05-24 2003-01-07 インタールーキン ジェネティックス インク 再狭窄の診断及び治療薬
EP1471931A4 (en) * 2001-08-24 2006-06-14 Maine Medical Ct Res Inst NON-TRADITIONAL EXPORT OF COPPER-DEPENDENT PRO-INFLAMMATORY CYTOKINES AND METHODS, COMPOSITIONS, AND KITS THEREOF
WO2004100987A2 (en) * 2003-05-06 2004-11-25 Regeneron Pharmaceuticals, Inc. Methods of using il-1 antagonists to treat neointimal hyperplasia
CN105467136B (zh) * 2008-05-30 2018-02-16 埃克斯生物科技公司 白细胞介素‑1α抗体及使用方法
CN107243077A (zh) * 2009-05-29 2017-10-13 爱克索马美国有限责任公司 IL‑1β抗体及其结合片段的心血管相关用途
JP5812669B2 (ja) 2011-04-27 2015-11-17 キヤノン株式会社 画像処理装置および画像処理方法およびコンピュータプログラム。

Also Published As

Publication number Publication date
WO2014055544A1 (en) 2014-04-10
HK1211960A1 (en) 2016-06-03
KR20210108496A (ko) 2021-09-02
EP3524621A1 (en) 2019-08-14
AU2013327501A1 (en) 2015-04-02
IL237765B (en) 2019-06-30
MX376241B (es) 2025-03-06
RU2671955C2 (ru) 2018-11-08
KR102296017B1 (ko) 2021-09-01
IL237765A0 (en) 2015-05-31
CN104684929A (zh) 2015-06-03
AU2013327501B2 (en) 2018-08-09
US20180057585A1 (en) 2018-03-01
US20140099321A1 (en) 2014-04-10
RU2015110635A (ru) 2016-11-27
MX2015004286A (es) 2015-08-06
JP6460993B2 (ja) 2019-01-30
JP2015531397A (ja) 2015-11-02
EP4628162A2 (en) 2025-10-08
CN113018431A (zh) 2021-06-25
KR20150063076A (ko) 2015-06-08
EP4628162A3 (en) 2025-12-03
US20210403548A1 (en) 2021-12-30
CA2886747A1 (en) 2014-04-10
EP2904010A1 (en) 2015-08-12
EP2904010A4 (en) 2016-06-01
KR102429919B1 (ko) 2022-08-05

Similar Documents

Publication Publication Date Title
CA2886747C (en) Treating vascular disease and complications thereof
US20250236669A1 (en) Antibodies That Bind Human Cannabinoid 1 (CB1) Receptor
US12116405B2 (en) Arthritis treatment
CA2849710C (en) Cachexia treatment
WO2012125680A1 (en) Methods of treating vasculitis using an il-17 binding molecule
AU2012236106A1 (en) Treatment for dermatological pathologies
AU2013327498A1 (en) Treatment of psychiatric conditions
US20130195877A1 (en) Treatment of cachexia by targeting interleukin-1 beta
HK40012735A (en) Treating vascular disease and complications thereof
HK40053657A (en) Treating vascular disease and complications thereof
TW202434625A (zh) Lag-3及pd-1/lag-3抗體
HK1199616B (en) Cachexia treatment

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928

EEER Examination request

Effective date: 20180928